Alectinib demonstrated a favorable safety profile and clinically meaningful response in patients with ALK-positive metastatic NSCLC and was granted accelerated approval by the United States Food and Drug Administration (FDA) on December 11, 2015 [7]. Here, ALK is linked to non-small cell lung carcinoma.